Company Filing History:
Years Active: 2022
Title: Cora Stegmann: Innovator in HCMV Research
Introduction
Cora Stegmann is a notable inventor based in Ulm, Germany. She has made significant contributions to the field of medical research, particularly in the development of therapies targeting human cytomegalovirus (HCMV). Her innovative work has led to the creation of a patent that holds promise for treating and preventing HCMV infections.
Latest Patents
Cora Stegmann holds a patent for HCMV entry inhibitors. The subject matter of her invention includes a soluble PDGFR-alpha-Fc chimera, a PDGFR-alpha derived peptide, an anti-PDGFR-alpha antibody, a PDGFR-alpha antibody fragment, or an anti-PDGFR-alpha non-Ig scaffold. This invention is designed to inhibit HCMV entry and can be utilized in treatment methods for subjects infected by HCMV, as well as in prophylactic methods for those who have not yet been infected.
Career Highlights
Cora Stegmann is currently associated with Aicuris Anti-infective Cures GmbH, where she continues her research and development efforts. Her work is pivotal in advancing therapeutic options for HCMV, a virus that poses significant health risks, especially in immunocompromised individuals.
Collaborations
Cora collaborates with esteemed colleagues, including Christian Sinzger and Kerstin Laib Sampaio. These partnerships enhance the research environment and contribute to the innovative solutions being developed at Aicuris.
Conclusion
Cora Stegmann's contributions to HCMV research through her patent and collaborative efforts underscore her role as a key innovator in the field. Her work not only advances scientific understanding but also holds the potential to improve patient outcomes in the fight against viral infections.